[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Incyte Corp (INCY)

Incyte Corp (INCY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 23,678,160
  • Shares Outstanding, K 199,782
  • Annual Sales, $ 5,141 M
  • Annual Income, $ 1,287 M
  • EBIT $ 1,611 M
  • EBITDA $ 1,704 M
  • 60-Month Beta 0.76
  • Price/Sales 4.56
  • Price/Cash Flow 18.97
  • Price/Book 4.17

Options Overview Details

View History
  • Implied Volatility 37.63% (-0.54%)
  • Historical Volatility 41.97%
  • IV Percentile 51%
  • IV Rank 31.94%
  • IV High 64.77% on 10/31/25
  • IV Low 24.90% on 08/08/25
  • Expected Move (DTE 7) 5.95 (5.12%)
  • Put/Call Vol Ratio 0.12
  • Today's Volume 86
  • Volume Avg (30-Day) 1,251
  • Put/Call OI Ratio 1.26
  • Today's Open Interest 22,637
  • Open Int (30-Day) 16,643
  • Expected Range 110.16 to 122.06

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 26 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $1.56
  • Number of Estimates 7
  • High Estimate $1.73
  • Low Estimate $1.25
  • Prior Year $1.31
  • Growth Rate Est. (year over year) +19.08%

Price Performance

See More
Period Period Low Period High Performance
1-Month
96.09 +21.72%
on 06/18/26
118.97 -1.69%
on 07/09/26
+11.57 (+10.98%)
since 06/10/26
3-Month
92.18 +26.88%
on 06/02/26
118.97 -1.69%
on 07/09/26
+20.89 (+21.74%)
since 04/10/26
52-Week
67.17 +74.13%
on 07/21/25
118.97 -1.69%
on 07/09/26
+46.62 (+66.28%)
since 07/10/25

Most Recent Stories

More News
Incyte to Report Second Quarter Financial Results

Incyte (Nasdaq:INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, July 28, 2026. The schedule for the press...

INCY : 115.87 (-2.24%)
Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio

Acquisition adds VGA039, a novel investigational monoclonal antibody in Phase 3 development for patients with von Willebrand disease (VWD), strengthening Incyte’s late-stage pipeline

INCY : 115.87 (-2.24%)
1 Mid-Cap Stock to Research Further and 2 We Avoid

1 Mid-Cap Stock to Research Further and 2 We Avoid

WSM : 223.51 (+1.70%)
INCY : 115.87 (-2.24%)
DRI : 206.24 (+2.97%)
1 Cash-Producing Stock with Solid Fundamentals and 2 We Turn Down

1 Cash-Producing Stock with Solid Fundamentals and 2 We Turn Down

INCY : 115.87 (-2.24%)
PAYC : 139.57 (+0.01%)
OII : 41.07 (+0.96%)
Stock Indexes Finish Lower as Chipmakers Sell Off

The S&P 500 Index ($SPX ) (SPY ) on Friday closed down -0.05%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down -0.09%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.09%. September...

SNDK : 1,874.11 (+0.85%)
STX : 908.92 (+2.12%)
WDC : 575.19 (-0.49%)
SPY : 751.93 (+0.03%)
ADSK : 208.60 (+0.01%)
MU : 977.14 (-1.46%)
QMCO : 9.79 (-5.87%)
NUTX : 184.39 (+0.56%)
QQQ : 721.68 (-0.22%)
FTNT : 158.74 (-3.05%)
NOW : 107.47 (-1.26%)
ADBE : 224.41 (+0.79%)
Stock Indexes Slip as Chipmakers Retreat

The S&P 500 Index ($SPX ) (SPY ) today is down -0.07%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.04%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.75%. September E-mini S&P futures...

AMAT : 595.98 (+1.24%)
AVGO : 399.24 (-0.47%)
SNDK : 1,874.11 (+0.85%)
INTU : 275.55 (+0.79%)
DDOG : 258.30 (-3.98%)
TXN : 309.66 (+0.37%)
$IUXX : 29,610.68 (-0.39%)
ASML : 1,789.29 (-0.83%)
ZNU26 : 109-035 (-0.14%)
MSFT : 382.61 (-0.46%)
ESU26 : 7,582.75 (-0.08%)
STX : 908.92 (+2.12%)
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis

If approved, Opzelura ® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD)...

INCY : 115.87 (-2.24%)
Stocks Mostly Lower on Weakness in Megacap Tech and Software Stocks

The S&P 500 Index ($SPX ) (SPY ) on Monday closed down -0.37%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.29%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.19%. September...

GOOGL : 353.96 (-1.37%)
AAPL : 313.78 (-0.77%)
SNDK : 1,874.11 (+0.85%)
ADI : 393.28 (-0.09%)
TSLA : 406.65 (+0.02%)
STX : 908.92 (+2.12%)
AMD : 547.44 (+0.13%)
DFTX : 45.25 (-6.60%)
SPY : 751.93 (+0.03%)
META : 669.76 (+6.06%)
NOC : 536.30 (+0.76%)
FRVO : 27.42 (+0.26%)
Incyte Stock: Is INCY Outperforming the Healthcare Sector?

Incyte has rallied the healthcare sector over the past year, and analysts remain moderately optimistic about its prospects.

XLV : 160.96 (-0.75%)
INCY : 115.87 (-2.24%)
INSM : 113.96 (-3.64%)
2 Growth Stocks to Add to Your Roster and 1 We Avoid

2 Growth Stocks to Add to Your Roster and 1 We Avoid

AVAV : 144.50 (-2.63%)
INCY : 115.87 (-2.24%)
AJG : 253.96 (+0.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. The company conducts its European clinical development operations in Geneva, Switzerland. Incyte's lead drug, Jakafi (ruxolitinib), is a first-in-class JAK1/JAK2...

See More

Key Turning Points

3rd Resistance Point 122.06
2nd Resistance Point 120.51
1st Resistance Point 119.52
Last Price 115.87
1st Support Level 116.98
2nd Support Level 115.43
3rd Support Level 114.44

See More

52-Week High 118.97
Last Price 115.87
Fibonacci 61.8% 99.18
Fibonacci 50% 93.07
Fibonacci 38.2% 86.96
52-Week Low 67.17

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.